It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
SARS-CoV-2 JN.1 with an additional L455S mutation on spike when compared with its parental variant BA.2.86 has outcompeted all earlier variants to become the dominant circulating variant. Recent studies investigated the immune resistance of SARS-CoV-2 JN.1 but additional factors are speculated to contribute to its global dominance, which remain elusive until today. Here, we find that SARS-CoV-2 JN.1 has a higher infectivity than BA.2.86 in differentiated primary human nasal epithelial cells (hNECs). Mechanistically, we demonstrate that the gained infectivity of SARS-CoV-2 JN.1 over BA.2.86 associates with increased entry efficiency conferred by L455S and better spike cleavage in hNECs. Structurally, S455 altered the mode of binding of JN.1 spike protein to ACE2 when compared to BA.2.86 spike at ACE2H34, and modified the internal structure of JN.1 spike protein by increasing the number of hydrogen bonds with neighboring residues. These findings indicate that a single mutation (L455S) enhances virus entry in hNECs and increases immune evasiveness, which contribute to the robust transmissibility of SARS-CoV-2 JN.1. We further evaluate the in vitro and in vivo virological characteristics between SARS-CoV-2 BA.2.86/JN.1 and EG.5.1/HK.3, and identify key lineage-specific features of the two Omicron sublineages that contribute to our understanding on Omicron antigenicity, transmissibility, and pathogenicity.
Here, the authors show that a single mutation in JN.1 spike, L455S, confers better spike cleavage and enhances virus infectivity in differentiated primary human nasal epithelial cells while increasing immune evasiveness, contributing to the efficient spread of JN.1.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details














1 The University of Hong Kong, Pokfulam, State Key Laboratory of Emerging Infectious Diseases, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Hong Kong Special Administrative Region, China (GRID:grid.194645.b) (ISNI:0000 0001 2174 2757)
2 Fudan University, Shanghai Sci-Tech Inno Center for Infection & Immunity, National Medical Center for Infectious Diseases, Huashan Hospital, Institute of Infection and Health, Shanghai, China (GRID:grid.8547.e) (ISNI:0000 0001 0125 2443); Fudan University, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, State Key Laboratory of Genetic Engineering, MOE Engineering Research Center of Gene Technology, School of Life Sciences, Shanghai Institute of Infectious Disease and Biosecurity, Shanghai, China (GRID:grid.8547.e) (ISNI:0000 0001 0125 2443)
3 Fudan University, Shanghai Fifth People’s Hospital, Shanghai Institute of Infectious Disease and Biosecurity, Institutes of Biomedical Sciences, Shanghai, China (GRID:grid.8547.e) (ISNI:0000 0001 0125 2443)
4 Pak Shek Kok, BayVax Biotech Limited, Hong Kong Science Park, New Territories, China (GRID:grid.194645.b)
5 The University of Hong Kong, Pokfulam, State Key Laboratory of Emerging Infectious Diseases, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Hong Kong Special Administrative Region, China (GRID:grid.194645.b) (ISNI:0000 0001 2174 2757); Hong Kong Science and Technology Park, Centre for Virology, Vaccinology and Therapeutics, Hong Kong Special Administrative Region, China (GRID:grid.194645.b)
6 Chinese Academy of Sciences, Key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Shenzhen, China (GRID:grid.9227.e) (ISNI:0000000119573309)
7 Fudan University, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, State Key Laboratory of Genetic Engineering, MOE Engineering Research Center of Gene Technology, School of Life Sciences, Shanghai Institute of Infectious Disease and Biosecurity, Shanghai, China (GRID:grid.8547.e) (ISNI:0000 0001 0125 2443)
8 Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Department of Infectious Diseases, Nanjing, China (GRID:grid.410745.3) (ISNI:0000 0004 1765 1045)
9 Fudan University, State Key Laboratory of Molecular Engineering of Polymers, Department of Macromolecular Science, Shanghai, China (GRID:grid.8547.e) (ISNI:0000 0001 0125 2443)
10 The University of Hong Kong, Pokfulam, State Key Laboratory of Emerging Infectious Diseases, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Hong Kong Special Administrative Region, China (GRID:grid.194645.b) (ISNI:0000 0001 2174 2757); Hong Kong Science and Technology Park, Centre for Virology, Vaccinology and Therapeutics, Hong Kong Special Administrative Region, China (GRID:grid.194645.b); The University of Hong Kong-Shenzhen Hospital, Department of Infectious Disease and Microbiology, Shenzhen, China (GRID:grid.440671.0) (ISNI:0000 0004 5373 5131)
11 The University of Hong Kong, Pokfulam, School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, Hong Kong Special Administrative Region, China (GRID:grid.194645.b) (ISNI:0000 0001 2174 2757); HKU-SIRI, Materials Innovation Institute for Life Sciences and Energy (MILES), Shenzhen, China (GRID:grid.194645.b)
12 The University of Hong Kong, Pokfulam, State Key Laboratory of Emerging Infectious Diseases, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Hong Kong Special Administrative Region, China (GRID:grid.194645.b) (ISNI:0000 0001 2174 2757); Hong Kong Science and Technology Park, Centre for Virology, Vaccinology and Therapeutics, Hong Kong Special Administrative Region, China (GRID:grid.194645.b); The University of Hong Kong-Shenzhen Hospital, Department of Infectious Disease and Microbiology, Shenzhen, China (GRID:grid.440671.0) (ISNI:0000 0004 5373 5131); Hainan Medical University-The University of Hong Kong Joint Laboratory of Tropical Infectious Diseases, Academician Workstation of Hainan Province, Haikou, China (GRID:grid.443397.e) (ISNI:0000 0004 0368 7493); Queen Mary Hospital, Pokfulam, Department of Microbiology, Hong Kong Special Administrative Region, China (GRID:grid.415550.0) (ISNI:0000 0004 1764 4144); Guangzhou Laboratory, Guangzhou, China (GRID:grid.459579.3)
13 The University of Hong Kong, Pokfulam, State Key Laboratory of Emerging Infectious Diseases, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Hong Kong Special Administrative Region, China (GRID:grid.194645.b) (ISNI:0000 0001 2174 2757); Hong Kong Science and Technology Park, Centre for Virology, Vaccinology and Therapeutics, Hong Kong Special Administrative Region, China (GRID:grid.194645.b); The University of Hong Kong-Shenzhen Hospital, Department of Infectious Disease and Microbiology, Shenzhen, China (GRID:grid.440671.0) (ISNI:0000 0004 5373 5131); Queen Mary Hospital, Pokfulam, Department of Microbiology, Hong Kong Special Administrative Region, China (GRID:grid.415550.0) (ISNI:0000 0004 1764 4144); Guangzhou Laboratory, Guangzhou, China (GRID:grid.459579.3)
14 The University of Hong Kong, Pokfulam, State Key Laboratory of Emerging Infectious Diseases, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Hong Kong Special Administrative Region, China (GRID:grid.194645.b) (ISNI:0000 0001 2174 2757); Hong Kong Science and Technology Park, Centre for Virology, Vaccinology and Therapeutics, Hong Kong Special Administrative Region, China (GRID:grid.194645.b); The University of Hong Kong-Shenzhen Hospital, Department of Infectious Disease and Microbiology, Shenzhen, China (GRID:grid.440671.0) (ISNI:0000 0004 5373 5131); HKU-SIRI, Materials Innovation Institute for Life Sciences and Energy (MILES), Shenzhen, China (GRID:grid.440671.0)